Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.73 USD
-0.07 (-1.41%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $4.77 +0.04 (0.85%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LPCN 4.73 -0.07(-1.41%)
Will LPCN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LPCN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for LPCN
Lipocine Initiates New ATM Offering, Ends Previous Agreement
LPCN, ADIL and CADL among pre-market losers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine's LPCN 2401 shows positive Phase 2 results in obesity trial